Article
Pediatrics
Tingyan He, Yu Xia, Ying Luo, Jun Yang
Summary: This study aimed to evaluate the efficacy and potential adverse effects of JAKi in patients with systemic juvenile idiopathic arthritis (SJIA). The results showed that JAKi may be an alternative or adjuvant agent for patients with persistently active disease, glucocorticoid-related adverse reactions, or SJIA-MAS.
FRONTIERS IN PEDIATRICS
(2023)
Review
Pharmacology & Pharmacy
Varvara Choida, Margaret Hall-Craggs, Bethany R. Jebson, Corinne Fisher, Maria Leandro, Lucy R. Wedderburn, Coziana Ciurtin
Summary: This study evaluated the role of biomarkers in predicting and assessing biologic treatment response and clinical remission in JIA, proposing new strategies for biomarker use. Various types of biomarkers were reviewed, identifying candidates with potential clinical utility and highlighting the need for new biomarker discovery and improved clinical applications.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Pediatrics
Emil Carlsson, Michael W. Beresford, Athimalaipet Ramanan, Andrew D. Dick, Christian M. Hedrich
Summary: Early treatment and frequent screening are crucial for controlling JIA-associated uveitis, which poses a significant risk for serious complications. The identification of specific risk factors for JIA-associated uveitis is a key focus of research as our understanding of pathogenic drivers is still incomplete. Genomic, transcriptomic, and proteomic factors have been identified as potential risk factors, and therapeutic strategies are being discussed.
Review
Biochemistry & Molecular Biology
Chao-Yi Wu, Huang-Yu Yang, Jing-Long Huang, Jenn-Haung Lai
Summary: Monocytes and macrophages play a crucial role in the pathogenesis of juvenile idiopathic arthritis (JIA), with their activation being linked to inflammation regulation and tissue repair mechanisms in the disease process.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Medicine, General & Internal
Pierre Quartier
Summary: Children with early onset juvenile idiopathic arthritis, especially with positive antinuclear antibodies, may develop chronic anterior uveitis, which requires regular slit lamp examination and prompt treatment. Therapy options range from local steroid treatment to systemic immunomodulatory therapy, tailored to individual patient needs, with involvement of expert ophthalmologists and pediatricians. Treatment should not be easily interrupted and may need to be intensified in certain cases for optimal disease control.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Immunology
Shuya Kaneko, Masaki Shimizu, Futaba Miyaoka, Asami Shimbo, Hitoshi Irabu, Mao Mizuta, Yasuo Nakagishi, Naomi Iwata, Junya Fujimura, Masaaki Mori, Tomohiro Morio
Summary: This study validates the correlation between laboratory markers reflecting disease activity of macrophage activation syndrome (MAS) and serum cytokine levels, and identifies valuable laboratory markers that change over time for a prompt MAS diagnosis.
CLINICAL IMMUNOLOGY
(2023)
Article
Ophthalmology
Achille Marino, Luca Marelli, Paolo Nucci, Roberto Caporali, Elisabetta Miserocchi
Summary: This study aimed to evaluate the efficacy and safety of subcutaneous tocilizumab in JIA patients with refractory uveitis. The results showed that SC-TCZ significantly reduced the rate of uveitis flare and achieved complete treatment response in some patients. Moreover, SC-TCZ was well-tolerated without any observed side effects.
OCULAR IMMUNOLOGY AND INFLAMMATION
(2023)
Article
Ophthalmology
Justine R. Smith, Janet M. Matthews, Diana Conrad, Anthony J. Hall, Rachael L. Niederer, Davinder Singh-Grewal, Mei-Ling Tay-Kearney, Jane M. Wells, Sophia L. Zagora, Peter J. McCluskey
Summary: The Australian and New Zealand-based uveitis-specialized ophthalmologists have developed 18 consensus statements for managing chronic anterior uveitis in children with JIA, providing regionally applicable advice for ophthalmic care.
CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
(2021)
Article
Pediatrics
Ellen Go, Mira van Veenendaal, Cedric Manlhiot, Rayfel Schneider, Brian W. McCrindle, Rae S. M. Yeung
Summary: This study describes the disease course of a small proportion of patients with both Kawasaki disease and systemic juvenile idiopathic arthritis, characterized by refractory Kawasaki disease, high prevalence of coronary artery dilatation, and shared immunopathology potentially linking the two conditions.
FRONTIERS IN PEDIATRICS
(2021)
Review
Rheumatology
Claas H. Hinze, Dirk Foell, Christoph Kessel
Summary: Systemic juvenile idiopathic arthritis (sJIA) is a disease characterized by severe systemic inflammation and arthritis. It poses challenges to rheumatologists treating pediatric and adult patients worldwide. Although treatment plans exist for classic sJIA, there is still a lack of clear treatment approaches for early sJIA without arthritis and complicated sJIA.
NATURE REVIEWS RHEUMATOLOGY
(2023)
Article
Medicine, General & Internal
Alberto Martini, Daniel J. Lovell, Salvatore Albania, Hermine Brunner, Kimme L. Hyrich, Susan D. Thompson, Nicolino Ruperto
Summary: Juvenile idiopathic arthritis (JIA) is the most common chronic inflammatory rheumatic condition of childhood, classified into seven categories. The pathogenesis of JIA involves autoimmune and autoinflammatory mechanisms, and the availability of new drugs has significantly improved treatment options.
NATURE REVIEWS DISEASE PRIMERS
(2022)
Article
Medicine, General & Internal
Chun-Hua Liao, Bor-Luen Chiang, Yao-Hsu Yang
Summary: This study retrospectively reviewed records of juvenile ERA patients in Taiwan from 2001 to 2020, finding a higher medication withdrawal rate among patients with ERA. Patients with poly-articular involvement were more likely to require the use of cDMARDs plus biologics. Those with a longer time interval between disease onset and initiation of cDMARDs were prone to flare-ups during biologics tapering.
FRONTIERS IN MEDICINE
(2021)
Article
Immunology
Jie Zheng, Yong Wang, Jun Hu
Summary: This study explores the shared gene signatures and potential molecular mechanisms of polyarticular juvenile idiopathic arthritis (pJIA) and autoimmune uveitis (AU) through data analysis and functional enrichment analysis. Neutrophil degranulation may be considered a shared pathogenic mechanism, and the roles of ARID1A gene and hsa-miR-146a are worthy of further study. Additionally, periodic inspection of kidney function is also important.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Medicine, General & Internal
Christoph Tappeiner, Han Sol Bae, Kai Rothaus, Karoline Walscheid, Arnd Heiligenhaus
Summary: The study aimed to analyze the occurrence and risk factors for macular edema (ME) in patients with juvenile idiopathic arthritis-associated uveitis (JIA-U). The results indicated that older age, worse eye conditions, and higher laser-flare photometry values were independent risk factors for ME manifestation.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Rheumatology
Rosemary G. Peterson, Rui Xiao, Karen E. James, Hannah Katcoff, Brian T. Fisher, Pamela F. Weiss
Summary: The study found significant variation in the use of biologics and glucocorticoids in children hospitalized with new-onset systemic JIA, with noticeable differences between hospitals. Despite increasing evidence supporting the use of biologics for improved outcomes, many children did not receive biologic treatment and a high rate of glucocorticoid exposure persisted.
ARTHRITIS CARE & RESEARCH
(2021)